Acurx Pharmaceuticals, Inc. (ACXP) Stock Score, Valuation & Financial Research

Acurx Pharmaceuticals, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for ACXP

Acurx Pharmaceuticals, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 1.26. These figures are a research snapshot, not a buy or sell recommendation.

What Acurx Pharmaceuticals, Inc. does

Acurx Pharmaceuticals, Inc. functions as a clinical-stage biopharmaceutical firm focused on developing innovative antibiotic treatments for bacterial infections. The company's primary drug candidate is ibezapolstat, an antibiotic that utilizes a novel mechanism of action by targeting the polymerase IIIC enzyme. Ibezapolstat has successfully completed Phase II clinical trials for addressing Clostridium difficile infections. Additionally, Acurx is progressing with ACX-375C, an investigational therapeutic suitable for both oral and injectable administration. This compound is being developed to combat various gram-positive bacteria, including resistant strains such as methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and penicillin-resistant Streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was established in 2017 and is headquartered in Staten Island, New York.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Acurx Pharmaceuticals is a clinical-stage biopharmaceutical company that does not currently generate revenue from product sales. Its business model relies on developing a new class of small molecule antibiotics, specifically ibezapolstat, and it intends to fund operations through capital raises while seeking partnerships with fully-integrated pharmaceutical companies for late-stage clinical trials and commercialization.

Products and services

  • The company is developing ibezapolstat, a novel small molecule antibiotic candidate designed to treat Clostridioides difficile infection (CDI).

Brands and product families

  • ibezapolstat — The company's primary antibiotic product candidate for the treatment of CDI. Source

Suppliers, materials and equipment

  • Contract Research Organizations and Contract Manufacturing Organizations — The company relies on unnamed third-party contract research organizations (CROs) to conduct clinical trials and contract manufacturing organizations (CMOs) for the production of its product candidates. Source

Business strengths to evaluate

  • Proprietary antibiotic class with potential for reduced CDI recurrence Source
  • Eligible for FDA QIDP and Fast Track designations providing regulatory exclusivity Source

Business risks and research considerations

  • History of operating losses and dependence on additional financing Source
  • Clinical trial failure or delays in regulatory approval Source

Sources: Company research source

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

ACXP financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 1.26
Market capitalization:
5.42M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -7.51M
Free cash flow:
USD -6.79M
Cash:
USD 10.66M
Total debt:
USD 0.00
EPS:
USD -3.55

What stands out

  • Free cash flow is USD -6.79M, negative for the stored period.
  • The balance sheet shows USD 10.66M of cash versus USD 0.00 of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a corporate distress warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 10.66M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for ACXP

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can ACXP fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is ACXP likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for ACXP to reach sustainable profitability?
  • What does the current corporate distress warning mean for the reliability or interpretation of ACXP's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 64% of the scoring inputs required for this public page are currently available.

How to research ACXP

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.